2seventy bio’s roots trace back to bluebird bio, a leader in gene and cell therapy

2seventy bio’s roots trace back to bluebird bio, a leader in gene and cell therapy that has successfully developed and commercialized four medicines for severe genetic diseases and cancer. Bluebird bio’s pioneering work laid the foundation for 2seventy bio’s focus on oncology, leveraging years of experience and innovation. In early 2021, bluebird bio made a strategic decision to split its operations to enhance the efficiency and speed of scientific advancements. This separation allowed bluebird bio to concentrate on gene therapy, while 2seventy bio emerged as an independent public company dedicated to oncology cell therapy. This move was aimed at fostering rapid progress and focused expertise in both domains.